Biotech · Private company · Los Angeles, CA, US

Max Biopharma, Inc.

Track this companyFree. Adds Max Biopharma, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials0None registered

Pipeline programs0None found yet

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

NIH awards2

Examination of anti-fibrotic and immune modulatory effects of Oxy210 for targeting cystic fibrosisFiscal year 2026 · $364.9KNIH RePORTER 1R43HL184363-01A1 · fetched Nov 12, 2026
Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitisFiscal year 2024 · $889.7KNIH RePORTER 5R44DK136405-02 · fetched Nov 12, 2026